What are the recommended acute and chronic treatment options for supraventricular tachycardia (SVT) in hemodynamically stable and unstable patients?

SVT Treatment

For hemodynamically stable SVT, start with vagal maneuvers followed immediately by adenosine 6 mg IV push if unsuccessful; for hemodynamically unstable patients, proceed directly to synchronized cardioversion without delay. 1

Acute Management Algorithm

Hemodynamically Unstable Patients

(hypotension, altered mental status, shock, chest pain, acute heart failure)

Synchronized cardioversion is the definitive treatment and should be performed immediately. 1 This approach avoids complications from antiarrhythmic drugs and restores sinus rhythm in essentially all patients. 1

• Exception: If the tachycardia is regular with narrow QRS complex, adenosine may be considered first before cardioversion, though this should not delay definitive treatment. 1, 2
• Energy dosing: Start with 50-100 J for SVT, increasing stepwise if unsuccessful. 1
• Critical caveat: Have cardioversion immediately available even when attempting adenosine, as adenosine can precipitate atrial fibrillation with rapid ventricular response. 1

Hemodynamically Stable Patients

First-Line: Vagal Maneuvers 1

• Modified Valsalva maneuver (most effective): Patient supine, bearing down against closed glottis for 10-30 seconds, generating 30-40 mm Hg intrathoracic pressure. Success rate ~43% in recent data, 27.7% when combined with other maneuvers. 1, 3
• Carotid sinus massage: After confirming no bruit, apply steady pressure over right or left carotid sinus for 5-10 seconds. 1
• Diving reflex: Apply ice-cold wet towel to face. 1
• Never apply pressure to eyeballs - this is dangerous and abandoned. 1

Second-Line: Adenosine 1

Adenosine is the drug of choice when vagal maneuvers fail, with 90-95% conversion success for AVNRT/AVRT. 1

• Dosing: 6 mg rapid IV push through large vein (antecubital), followed by 20 mL saline flush. If no conversion in 1-2 minutes, give 12 mg rapid IV push. 1
• Critical safety point: Defibrillator must be immediately available as adenosine can precipitate atrial fibrillation that may conduct rapidly and cause ventricular fibrillation. 1
• Side effects occur in ~30% but are brief (<1 minute). 1
• Drug interactions: Reduce initial dose to 3 mg in patients on dipyridamole, carbamazepine, or with transplanted hearts. Larger doses needed with theophylline/caffeine. 1
• Contraindication: Avoid in asthma patients. 1

Third-Line: IV Calcium Channel Blockers or Beta-Blockers 1

IV diltiazem or verapamil are effective alternatives with 64-98% conversion rates. 1

• Particularly useful for patients who cannot tolerate beta-blockers or have recurrence after adenosine conversion. 1
• Slow infusion up to 20 minutes may reduce hypotension risk. 1
• Critical contraindications:
  • Do NOT use if any possibility of ventricular tachycardia or pre-excited atrial fibrillation (can cause hemodynamic collapse or ventricular fibrillation). 1
  • Avoid in systolic heart failure. 1

IV beta-blockers are reasonable alternatives with excellent safety profile, though less effective than calcium channel blockers. 1

Fourth-Line: Synchronized Cardioversion 1

When pharmacological therapy fails or is contraindicated in stable patients, synchronized cardioversion is highly effective (80-98% success) and should be performed after adequate sedation. 1

Special Situation: Pre-Excited Atrial Fibrillation (Wolff-Parkinson-White)

This is a life-threatening emergency requiring different management:

• Unstable patients: Immediate synchronized cardioversion. 1
• Stable patients: Use ibutilide or IV procainamide (NOT adenosine, NOT calcium channel blockers, NOT beta-blockers as first-line). 1
• Never use AV nodal blocking agents (adenosine, diltiazem, verapamil, digoxin) as they can enhance accessory pathway conduction and precipitate ventricular fibrillation. 1

Chronic/Ongoing Management

First-Line: Catheter Ablation 3, 4, 5

Catheter ablation is recommended as first-line therapy for recurrent symptomatic SVT with single-procedure success rates of 94.3-98.5%. 3, 4 This represents a major shift in recent guidelines, upgrading ablation to preferred status. 1, 6

• Curative in the majority of patients. 5
• Particularly recommended for AVNRT due to very low AV block risk. 6
• All patients treated for SVT should be referred to a heart rhythm specialist. 5

Second-Line: Long-Term Pharmacotherapy 1

For patients who decline or are not candidates for ablation, oral beta-blockers, diltiazem, or verapamil are useful for ongoing management. 1

• Both diltiazem and verapamil are well-tolerated and effective alternatives to ablation. 1
• Monitor for bradyarrhythmias and hypotension when initiating therapy. 1
• Avoid in systolic heart failure. 1

Common Pitfalls to Avoid

1. Never delay cardioversion in unstable patients to attempt pharmacological conversion. 1
2. Always have defibrillator ready when giving adenosine due to risk of precipitating dangerous atrial fibrillation. 1
3. Never use calcium channel blockers or beta-blockers if any suspicion of pre-excited atrial fibrillation or ventricular tachycardia. 1
4. Recognize that post-conversion premature complexes may reinitiate tachycardia, requiring antiarrhythmic drugs to prevent recurrence. 1
5. Do not use amiodarone or digoxin for acute narrow-complex SVT management - these are no longer recommended. 1